Advanced searches left 3/3

Enalapril - DOAJ

Summarized by Plex Scholar
Last Updated: 07 July 2022

* If you want to update the article please login/register

Enalapril Diminishes the Diabetes-Induced Changes in Intestinal Morphology, Intestinal RAS and Blood SCFA Concentration in Rats

We hypothesized that diabetes promotes the intestinal renin u2013angiotensin system, contributing to gut pathology. The Twelve-week-old male rats were divided into three groups: controls, diabetic, and diabetic treated with enalapril were divided into three groups: controls, diabetic, and diabetic treated with enalapril. The colon and the jejunum were characterized by morphology and RAS expression by Histological examination and RT-qPCR. The stools, portal, and systemic blood samples of SCFA and TMAO were analyzed for stools, portal, and systemic blood. The diabetic rats showed hyperplastic shifts in jejunal and colonic mucosa, increased plasma SCFA, and marginally elevated plasma TMAO in comparison to the controls. In the jejunum, Diabetic rats had a lower amount of Mas receptor and angiotensinogen, but diabetic rats had more expression, while in diabetic rats, the expression of MasR and renin was higher. MasR-treated rats with Enalapril had a reduced incidence in the colon. The expression of AT1a, AT1b, and AT2 receptors was similar between the three groups. Future studies must investigate the clinical significance of intestinal pathology in diabetes to determine the clinical relevance of intestinal pathology in diabetes.

Source link: https://doi.org/10.3390/ijms23116060


Model-dependent pharmacokinetic analysis of enalapril administered to healthy adult volunteers using orodispersible minitablets for use in pediatrics

Objectives: To compare and examine any differences in entalapril's PK, as well as a market-approved reference tablet formulation based on the PK compartment model and a validated least square minimization scheme of parameter estimation. With the inclusion of an integrated lag time parameter, enalapril data were tested with one- and two-compartment models for the first order of absorption and elimination, as well as an implicit lag time parameter. The log-transformed PK parameters were compared statistically by the two-sided paired t-test with the same degree of significance as P 0. 05. Comparing PK parameters including rate constants of absorption and elimination, number of sources, and lag between the three treatments showed significant differences in tlag between treatments B and A only. enalapril treated with 240 mL water appeared 4 minutes earlier in serum than the reference formulation.

Source link: https://doaj.org/article/a184d1a090034d5e8aa30d4b795882d3


Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats

BACKGROUND: The quest for new therapies for chronic kidney disease has resulted in the development of therapies that integrate traditional renin-angiotensin-aldosterone-system inhibitors with other drugs that may have promise in disease control. Methods: We investigated the effects of adding the endothelin-A receptor antagonist atrasentan to a previously studied combination of enalapril and paricalcitol on cardiac and renal measurements in rats made uremic by renal ablation. Individual therapy with the medications reduced heart tissue volume, and combined therapy decreased cardiomyocyte size to normal levels.

Source link: https://doi.org/10.1159/000355811


Angiotensin-converting enzyme inhibitor, Enalapril, inhibits tumor growth and potentiates the antitumor efficacy of 5-FU in colorectal cancer

In a vivo model, we investigated Enalapril's CRC's CRC the therapeutic potency of targeting ACE by Enalapril. RESULTS: Enalapril reduced tumor formation and increased tumor necrosis; this effect was more apparent in Enalapril's combined 5-FU combination. While lowering total thiol group numbers, SOD, and CAT enzyme activity, ACE inhibitors also increased MDA level as an oxidative stress indicator. CONCLUSION: Our results reveal new information about the renin-u2013angiotensin system as a promising therapeutic option in combination with existing therapeutic agents 5-FU in the treatment of CRC.

Source link: https://doi.org/10.32113/wcrj_20225_2314


Simultaneous Determination of Hydrochlorothiazide and Enalapril Maleate in Pharmaceutical Formulations Using Fourier Transform Infrared Spectrometry

In binary solid pharmaceutical formulations, a new Fourier Transform-Infra Red spectrometric system was designed for assaying hydrochlorothiazide and enalapril maleate. For calibration of derivative spectral data, the Multivariate Partial Least Squares procedure was used. In the spectral range of 1550-1800 cm-1, A 4-levels full factorial design of binary standard HCT and ENM was developed and used for calibration. HCT and ENM's correlation coefficients were 0. 990 and 0. 9995, respectively, and Relative Standard Deviation, which was 1. 9 percent and 1. 3 percent. ENM and HCT detection limits of detection were 0. 54 and 0. 99 mg/mL respectively.

Source link: https://doaj.org/article/0b3b07a5e276449b818ed1b1d90c3d1c


Enalapril and Enalaprilat Pharmacokinetics in Children with Heart Failure Due to Dilated Cardiomyopathy and Congestive Heart Failure after Administration of an Orodispersible Enalapril Minitablet (LENA-Studies)

In five European countries using a novel age-appropriate formulation of enalapril orodispersible minitablets, phase II/III open-label, multicenter pharmacokinetic bridging trials were carried out in pediatric patients with heart failure due to dilated cardiomyopathy and congenital heart disease. Enalapril and its active metabolite enalaprilat were described in the primary aim of describing PK parameters of the drug enalapril and its active metabolite enalaprilat. The primary PK endpoint analysis included 102 patients and 89 patients. Enalapril's incidence and presence were identified, as potential PK modifying factors, as well as etiology and age.

Source link: https://doi.org/10.3390/pharmaceutics14061163


Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study

At a 6-month follow-up, to compare the safety and effectiveness of valsartan/sacubitril against enalapril in patients with acute heart disease. Methods: Patients with acute decompensated heart failure with reduced ejection fraction were included in this prospective, single center, and observational study that was conducted in India between September 2017 and February 2020. 100 patients in the ARNI and ACEI groups were included in the new study, with 100 in the ARNI and ACEI groups each. In the ARNI group and the ACEI group, respectively, the mean age of the population was 61. 2 years and 62. 6 years. In the ACEI group, the mean maximum tolerated dose by population in the ARNI group was 203. 6 mg and 8. 9 mg. In the ACEI group, the incidence of heart failure was significantly higher than in the ARNI group, despite the ARNI group's similarity. Conclusion: At the end of the 6 months follow-up to the ACEI group, the ARNI study group produced enhanced safety and efficacy findings.

Source link: https://doi.org/10.1016/j.ihj.2022.04.003


Curative effects of enalapril combined with folic acid tablets on hypertension and its mechanism

Methods: A total of 92 cases of H type hypertension patients were randomly divided into the observation group and control group, while the control group, on the other hand, was treated with enalapril maleate tablets for therapy, compared to two groups of serum homocysteine cysteine, inflammatory factor, and vascular endothelial injury-related measures of change. Conclusion: In a certain degree, the H type hypertension patients and enalapril maleate tablets in the therapy can improve the patient's blood pressure, lower Hcy levels, promote endothelial function, and reduce inflammation, but the inflammatory reaction can be reduced if combined with a dose of folic acid, which can be reduced.

Source link: https://doaj.org/article/c7563abc46fa4e93b23e7c8f5bf24adc


Enalapril protects endothelial cells against induced apoptosis in Alzheimer′s disease

Also, the mean u00b1 SD of untreated HUVECs by enalapril had significant increases in dissolved NO2 / NO3 metabolites in the culture media of untreated HUVECs by enalapril, as compared to control, although the rate of nitric oxide steadily decreased when enalapril was introduced in culture both in the pretreatment and the post-treatment group. Conclusion: It could be assumed that EC treated with sera from AD patients triggers apoptosis in HUVECs, which could be reversed by enalapril pretreatment.

Source link: https://doaj.org/article/c396ed7efc0548a3881177e63c1a6534


Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence

To achieve safe blood pressure control, several large intervention trials in high-risk patient populations have revealed that an average of 2–4 antihypertensive agents is needed. Combination therapy may be considered a first-choice in patients with elevated blood pressure elevated in patients with elevated cardiovascular risk and those with shallower levels of blood pressure elevation are often attributed to a variety of risk factors, such as subcutaneous organ damage, renal dysfunction, or cardiovascular disease related to cardiovascular disease. A series of clinical trials have shown that a combination of lercanidipine and enalapril has greater safety and tolerability than monotherapy with either agents. The benefits of combining therapy include increased adherence to therapy and reduced blood pressure variability, which are both beneficial and minimized.

Source link: https://doaj.org/article/892cc1ac73a04c44871a44529571eb45

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions